Mesenchymal-like adherent stromal cell therapy - Celularity
Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Celularity
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Unspecified
Most Recent Events
- 15 Oct 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral), prior to October 2024 (Celularity pipeline, October 2024)
- 15 Oct 2024 Preclinical trials in Unspecified in USA (Parenteral), prior to October 2024 (Celularity pipeline, October 2024)